Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| C6271001-C1 | Other Identifier | Alias Study Number | |
| C6271001-C1A | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.
This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A | Experimental | Low Dose COVID-19 Vaccine (1a) |
|
| Arm B | Experimental | Low Dose COVID-19 Vaccine ( 1b) |
|
| Arm C | Experimental | Low Dose COVID-19 Vaccine ( 1c) |
|
| Arm D | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 1) |
|
| Arm E | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2) |
|
| Arm F | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Investigational Influenza Vaccine | Biological | Investigational Influenza Vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Day 7 | |
| Percentage of participants reporting prompted systemic events within 7 days following investigational product administration | Day 7 | |
| Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration | 1 month | |
| Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| GMTs before and through 1 month following investigational product administration | Before vaccination through to 1 month after vaccination |
Not provided
Inclusion criteria:
Exclusion criteria:
Refer to the study contact for further eligibility details
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim Clinical Trials, LLC | Anaheim | California | 92801 | United States | ||
| Orange County Research Center |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Arm G | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4) |
|
| Arm H | Active Comparator | Licensed COVID-19 Vaccine |
|
| Arm I | Active Comparator | Licensed Influenza Vaccine (1) |
|
| Arm J | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5) |
|
| Arm K | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6) |
|
| Arm L | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7) |
|
| Arm M | Active Comparator | Licensed COVID-19 Vaccine |
|
| Arm N | Active Comparator | Licensed Influenza Vaccine (2) |
|
| Arm AA | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6) |
|
| Arm BB | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4) |
|
| Arm CC | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7) |
|
| Arm DD | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2) |
|
| Arm EE | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3) |
|
| Arm FF | Active Comparator | Licensed COVID-19 Vaccine |
|
| Arm GG | Active Comparator | Licensed Influenza Vaccine (3) |
|
| Arm HH | Active Comparator | Licensed Influenza Vaccine (2) |
|
| Arm II | Experimental | Low Dose COVID-19 Vaccine ( 1b) |
|
| Arm JJ | Experimental | Low Dose COVID-19 Vaccine ( 1c) |
|
| Arm KK | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4) |
|
| Arm LL | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7) |
|
| Arm MM | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2) |
|
| Arm NN | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3) |
|
| Arm OO | Experimental | Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5) |
|
| Arm PP | Experimental | Medium Dose Investigational Influenza Vaccine (1) |
|
| Arm QQ | Experimental | High Dose Investigational Influenza Vaccine (2) |
|
| Arm RR | Active Comparator | Licensed COVID-19 Vaccine |
|
| Arm SS | Active Comparator | Licensed Influenza Vaccine (3) |
|
| Investigational COVID-19 Vaccine | Biological | Investigational COVID-19 Vaccine |
|
| Investigational Influenza and COVID-19 Combination Vaccine | Combination Product | Investigational Combined Influenza and COVID-19 Vaccine |
|
| Licensed Influenza Vaccine 1 | Biological | Licensed Influenza Vaccine 1 |
|
| Licensed Influenza Vaccine 2 | Biological | Licensed Influenza Vaccine 2 |
|
| Licensed Influenza Vaccine 3 | Biological | Licensed Influenza Vaccine 3 |
|
| Licensed COVID-19 Vaccine | Biological | Pfizer-BioNTech COVID-19 Vaccine |
|
| Lake Forest |
| California |
| 92630 |
| United States |
| Artemis Institute for Clinical Research | Riverside | California | 92503 | United States |
| Artemis Institute for Clinical Research | San Diego | California | 92103 | United States |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | United States |
| Clinical Research Consulting | Milford | Connecticut | 06460 | United States |
| Alliance for Multispecialty Research, LLC | Doral | Florida | 33172 | United States |
| Indago Research & Health Center, Inc | Hialeah | Florida | 33012 | United States |
| Miami Dade Medical Research Institute, LLC | Miami | Florida | 33176 | United States |
| Palm Springs Community Health Center | Miami Lakes | Florida | 33014 | United States |
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | United States |
| East-West Medical Research Institute | Honolulu | Hawaii | 96814 | United States |
| Clinical Research Professionals | Chesterfield | Missouri | 63005 | United States |
| Las Vegas Clinical Trials | North Las Vegas | Nevada | 89030 | United States |
| Upstate Global Health Institute | East Syracuse | New York | 13057 | United States |
| University of Rochester Medical Center | Rochester | New York | 14642 | United States |
| Trial Management Associates - Wilmington - Floral Parkway | Wilmington | North Carolina | 28403 | United States |
| Centricity Research Columbus Ohio Multispecialty | Columbus | Ohio | 43213 | United States |
| DM Clinical Research - Philadelphia | Philadelphia | Pennsylvania | 19107 | United States |
| Coastal Carolina Research Center | North Charleston | South Carolina | 29405 | United States |
| AMR Clinical | Knoxville | Tennessee | 37909 | United States |
| AMR Clinical | Knoxville | Tennessee | 37920 | United States |
| Clinical Research Associates Inc | Nashville | Tennessee | 37203 | United States |
| Headlands Horizons, LLC dba Headlands Research-Brownsville | Brownsville | Texas | 78526 | United States |
| DM Clinical Research- Cyfair | Houston | Texas | 77065 | United States |
| SMS Clinical Research | Mesquite | Texas | 75149 | United States |
| Dynamed Clinical Research, LP d/b/a DM Clinical Research | Tomball | Texas | 77375 | United States |
| J. Lewis Research, Inc. / Foothill Family Clinic | Salt Lake City | Utah | 84109 | United States |
| J. Lewis Research, Inc. / Foothill Family Clinic South | Salt Lake City | Utah | 84121 | United States |
| Charlottesville Medical Research | Charlottesville | Virginia | 22911 | United States |
| Kaiser Permanente Washington Health Research Institute (KPWHRI) | Seattle | Washington | 98101 | United States |
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D008171 | Lung Diseases |
Not provided
Not provided